In fact, the combination strategy of FTase inhibitors with group I PAK inhibitors is effective in human melanoma, lung, and colon cancer.555 Another farnesyltransferase inhibitor lonafarnib exhibit sufficiently melanoma cell growth inhibition and apoptosis induction after the combination with the pan-RAF inhibitor sorafenib.556 Besides tipifarnib and lonafarnib, other inhibitors including lestaurinib, tandutinib, and PKC 412 have also been designed and tested under early-phase clinical evaluation in acute myeloid leukemia (AML).557 The ongoing clinical trials are listed in Table 2. The gene discussed is PRRT2; the disease is melanoma.